Two Sigma Investments LP Decreases Position in Humacyte, Inc. (NASDAQ:HUMA)

Two Sigma Investments LP lessened its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 14.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 919,097 shares of the company's stock after selling 149,142 shares during the quarter. Two Sigma Investments LP owned 0.73% of Humacyte worth $4,641,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in HUMA. Vontobel Holding Ltd. acquired a new stake in Humacyte in the 4th quarter valued at approximately $50,000. Petros Family Wealth LLC acquired a new stake in shares of Humacyte in the fourth quarter valued at $50,000. Syon Capital LLC purchased a new stake in shares of Humacyte in the 4th quarter valued at $54,000. Ameriprise Financial Inc. acquired a new position in Humacyte during the 4th quarter worth about $58,000. Finally, Hsbc Holdings PLC acquired a new position in Humacyte during the 4th quarter worth about $62,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HUMA has been the subject of several research reports. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research report on Tuesday, May 13th. HC Wainwright started coverage on shares of Humacyte in a report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price objective for the company. Wall Street Zen upgraded shares of Humacyte from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Benchmark decreased their price target on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $11.71.

Insider Transactions at Humacyte

In other news, Director Kathleen Sebelius acquired 50,000 shares of the company's stock in a transaction on Tuesday, April 8th. The shares were bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the purchase, the director now owns 91,207 shares of the company's stock, valued at $120,393.24. This represents a 121.34% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Dale A. Sander bought 20,000 shares of Humacyte stock in a transaction dated Thursday, April 10th. The stock was purchased at an average price of $1.53 per share, with a total value of $30,600.00. Following the purchase, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. This trade represents a 97.09% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 83,993 shares of company stock worth $118,224. Company insiders own 5.10% of the company's stock.

Humacyte Trading Down 3.2%

Shares of NASDAQ HUMA traded down $0.09 during trading hours on Friday, reaching $2.68. The stock had a trading volume of 5,786,393 shares, compared to its average volume of 3,779,580. The firm has a 50-day moving average of $1.71 and a 200-day moving average of $3.27. The firm has a market cap of $415.72 million, a price-to-earnings ratio of -2.00 and a beta of 1.64. Humacyte, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $9.79.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. On average, equities analysts predict that Humacyte, Inc. will post -1.27 EPS for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.